Identification, Synthesis, and Strategy for Minimization of Potential Impurities in the Preclinical Anti-HBV Drug Y101
Citations Over Time
Abstract
The identification of actual, potential, and theoretical impurities of N-[N-benzoyl-O-(2-dimethylaminoethyl)-l-tyrosyl]-l-phenylalaninol (Y101), a preclinical anti-HBV drug, is described in this article. The impurities were monitored by HPLC, and their structures were established on the basis of NMR, IR, and MS. Most of the impurities were synthesized, and their assigned constitutions were confirmed by HPLC co-injection with an ordinary column (Phenomenex Gemini, 250 mm × 4.6 mm, 5 μm) or a chiral column (DAICEL Chiralcel OD-H). According to the synthetic route, the origins of all of these related impurities were analyzed, and some practical strategies were applied for minimizing these impurities to the level accepted by the International Conference on Harmonization (ICH), and therefore, these strategies can be well applied to the quality control in Y101 clinical sample manufacture.
Related Papers
- Effect of impurities on optical qualities of KDP crystal(2004)
- → Addition of anion impurities as a method of freeing alkali halide crystals from the effects of divalent cation impurities(1968)
- → Control of impurity concentration in liquid metals by neutron scattering(2011)
- Effect of hemoglobin variants on the derermination of glycohemoglobin by two high performance liquid chromatography-based methods(2009)
- 밀크씨슬추출물 내 실리마린의 UPLC 분석법 확립(2018)